Home/Pipeline/Spesolimab (Spevigo)

Spesolimab (Spevigo)

Generalized Pustular Psoriasis (GPP)

MarketedActive

Key Facts

Indication

Generalized Pustular Psoriasis (GPP)

Phase

Marketed

Status

Active

Company

Boehringer Ingelheim

About Boehringer Ingelheim

Boehringer Ingelheim is a major, privately-held German pharmaceutical powerhouse with a significant global footprint in human and animal health. Its strategy is built on deep research expertise across multiple therapeutic modalities, including immunology, cardiometabolic diseases, and oncology. The company maintains a robust pipeline and invests heavily in R&D, supported by a stable financial position due to its private ownership structure. Its key challenges include navigating intense therapeutic area competition and the inherent risks of late-stage clinical development.

View full company profile

Therapeutic Areas

Cardio-Renal-Metabolism Immunology Oncology Mental Health Animal Health

Other Generalized Pustular Psoriasis (GPP) Drugs

Drug	Company	Phase	Status
Imsidolimab	Vanda Pharmaceuticals	BLA Filed	FDA Application Under Review